news
Crohn’s disease: discovery of two distinct molecular subtypes
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
List view / Grid view
Drug Development
article
Unlocking the potential of smart antibodies
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
podcasts
Scaling genetic medicine with tRNA
Tune into this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
article
AI-driven drug discovery: insights from Cresset
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
news
Novel nasal spray effectively prevents influenza infection
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
news
New monoclonal antibody drug could combat antimicrobial resistance
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
news
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
news
NSD2’s role in driving prostate cancer development
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
article
Rapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
article
’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
article
Women in STEM with Kristina Torfgard
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.
news
Novel compound for targeted alpha therapy
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.